Prenatal choline trial links supplementation to better child cognition

A randomized clinical trial found that children whose mothers received phosphatidylcholine during pregnancy scored nearly eight points higher on standardized cognitive tests and had fewer reported social-withdrawal problems than children whose mothers received a placebo. Researchers assigned 206 pregnant women at 16 weeks of pregnancy to receive either 9,000 milligrams of phosphatidylcholine daily or a placebo until delivery. The study, published in the American Journal of Obstetrics & Gynecology, followed children’s behavior from 18 months to 4 years of age and assessed cognition at ages 3 and 4. The investigators described the trial as the largest randomized clinical trial of prenatal choline supplementation, while cautioning that about one-third of participants did not complete the study through the four-year assessments and that longer follow-up is needed.

Phosphatidylcholine is a form of choline, an essential nutrient that supports brain development. The researchers investigated whether increasing maternal intake during pregnancy could improve early child development, building on previous evidence suggesting that choline participates in the formation of connections between brain cells. All women in the trial were encouraged to take standard prenatal vitamins and follow a diet containing eggs, meat and other natural sources of phosphatidylcholine. The experiment therefore compared prenatal supplementation with placebo within the context of prenatal vitamins and a diet that already included choline-containing foods, rather than comparing a supplemented diet with a diet lacking choline.

Children’s behavior was assessed repeatedly from 18 months through 4 years, and investigators measured cognitive performance at ages 3 and 4. The cognitive assessments evaluated overall intellectual performance, including working memory and visual-spatial skills. Behavioral outcomes included social withdrawal, language development, broader social functioning and attention problems. Researchers also examined the frequency of behavioral profiles and language difficulties commonly associated with autism spectrum disorder. The supplement did not significantly reduce attention problems, which was another primary outcome of the study, so the results were not uniform across all developmental measures evaluated.

Among children whose parents completed the relevant behavioral assessments, 4% of those in the supplement group had elevated social-withdrawal problems, compared with 24% in the placebo group. The behaviors assessed for social withdrawal included a limited interest in other people, withdrawal from social activities and reduced eye contact. Children in the supplement group also averaged nearly eight points higher on the standardized cognitive tests than children in the placebo group. Robert Freedman, the study’s senior author and a professor of psychiatry at the University of Colorado Anschutz, described the cognitive result as an increase of about eight points in overall measured IQ at age 4. He said the difference placed significantly more children in higher IQ percentiles on the test used.

The investigators also observed significantly fewer children with the combined behavioral profiles and language difficulties commonly associated with autism spectrum disorder in the supplement group. This result concerns an assessment of behavior and language rather than a reported diagnosis of autism. The supplied research release did not identify the supplement as a treatment or prevention strategy for autism, and the finding should not be interpreted as evidence that prenatal phosphatidylcholine prevents the condition. The study’s reported group differences included the frequency of elevated social-withdrawal problems and children’s average scores on the standardized cognitive battery, while the separate attention-problem outcome did not show a significant reduction.

One proposed biological explanation centers on a receptor made by the CHRNA7 gene in developing nerve cells. According to Freedman, choline in the baby’s circulation comes from choline eaten by the mother and activates this receptor before birth. The receptor helps developing neurons develop the machinery they need to receive signals from other nerve cells. Freedman said that many mothers do not obtain enough choline in their diets to fully provide the fetal circulation with the amount needed to complete the activation of those neurons. He also argued that it is nearly impossible to obtain enough choline through a normal diet to produce the receptor activation described in the study, using the example of eating 10 eggs a day. This mechanism was the researchers’ explanation for the trial findings; the release did not separately establish the pathway as the cause of differences in each participating child.

The phosphatidylcholine dose tested in the trial was higher than the amount Freedman said he now recommends. Women received 9,000 milligrams of phosphatidylcholine daily, while Freedman stated that the study team recommended 7,200 milligrams of phosphatidylcholine or 900 milligrams of choline itself. The news release said both forms are available in drug and grocery stores. This lower-dose statement came from Freedman’s interpretation of the study results; the supplied evidence did not include a separate trial showing that 7,200 milligrams of phosphatidylcholine or 900 milligrams of choline would reproduce the outcomes observed with the randomized regimen. Nor did the release establish a universal supplementation guideline for pregnant women.

Researchers reported no significant supplement-related safety problems among mothers or children. Several features of the study nevertheless limit how confidently the findings can be generalized. Approximately one-third of enrolled participants did not complete the study through the four-year assessments, meaning the group available for later follow-up was smaller than the original cohort of 206 mothers and their children. The cognitive difference therefore was not a measurement in all 206 participating families. Attrition may also have affected the comparisons if the children whose families remained and completed follow-up differed from those who withdrew or were not assessed. In addition, parents reported the children’s behavioral symptoms rather than all symptoms being established through a uniform direct diagnostic assessment, which introduces the possibility of reporting bias. The release did not provide confidence intervals or a detailed description of how missing data were handled.

Published on October 19, 2026, the study provides randomized evidence that prenatal phosphatidylcholine supplementation may influence selected cognitive and behavioral outcomes through age 4, but the findings require careful interpretation. The trial followed children only through their fourth year, so it cannot establish whether the measured differences continue into school age or adulthood. The behavioral results also depended on parent reports, and the substantial loss to follow-up means the children included in the final comparisons represented only part of the original enrolled cohort. Researchers said larger studies with longer follow-up are needed to determine whether the observed differences persist as children grow. The work adds to evidence concerning choline and fetal brain development, but the scope of this trial—206 pregnant women, supplementation beginning at 16 weeks and continuing until delivery, and follow-up through age 4—should define the strength and reach of its conclusions.

Subject of Research: Randomized trial of prenatal phosphatidylcholine supplementation and child cognition and behavior through age 4

Article Title: Prenatal supplement linked to improved child cognition and social behavior, study says

Article References: Prenatal supplement linked to improved child cognition and social behavior, study says. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: prenatal choline, phosphatidylcholine, child cognition, social behavior, randomized clinical trial, maternal nutrition, fetal brain development, working memory, language development, CHRNA7, Prenatal, supplement